INNOVENT BIOLGCS UNSP/ADR

HUTCHMED and Innovent announced that their new drug application for the combination of fruquintinib and sintilimab for the treatment of advanced renal cell carcinoma has been accepted for review in China. The combination showed promising efficacy and a tolerable safety profile in a Phase Ib/II study.

Related tickers: HCM, IVBIY.

The article discusses the growing dominance of Chinese pharmaceutical companies in the development of bispecific antibody drug conjugates (BsADCs), a novel class of cancer therapeutics. It highlights the significant number of BsADC clinical trials being conducted in China and the advancements made by various companies in this field.

Related tickers: BMY, CELGr, AMGN, AZN, IVBIY.